Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
103.18
-4.57 (-4.24%)
Official Closing Price
Updated: 4:10 PM EDT, Mar 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
↗
February 21, 2025
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.
Via
Benzinga
Wondering what's happening in today's after-hours session?
↗
February 20, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From
Glaukos Corporation
Via
Business Wire
Earnings Scheduled For February 20, 2025
↗
February 20, 2025
Via
Benzinga
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
↗
February 19, 2025
Via
Benzinga
Peering Into Glaukos's Recent Short Interest
↗
February 12, 2025
Via
Benzinga
How Is The Market Feeling About Glaukos?
↗
January 27, 2025
Via
Benzinga
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
↗
January 23, 2025
Via
Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
January 23, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
January 14, 2025
From
Glaukos Corporation
Via
Business Wire
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
↗
January 13, 2025
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.
Via
Benzinga
Topics
Fraud
What 11 Analyst Ratings Have To Say About Glaukos
↗
December 31, 2024
Via
Benzinga
(GKOS) - Analyzing Glaukos's Short Interest
↗
December 26, 2024
Via
Benzinga
How Is The Market Feeling About Glaukos?
↗
December 03, 2024
Via
Benzinga
Analyst Scoreboard: 5 Ratings For Glaukos
↗
November 26, 2024
Via
Benzinga
How Is The Market Feeling About Glaukos?
↗
October 30, 2024
Via
Benzinga
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
↗
December 31, 2024
Via
Benzinga
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
December 23, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 17, 2024
From
Glaukos Corporation
Via
Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7
↗
December 07, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024.
Via
Talk Markets
Topics
Stocks / Equities
A Closer Look at 7 Analyst Recommendations For Glaukos
↗
October 14, 2024
Via
Benzinga
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
December 06, 2024
Via
Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
↗
December 02, 2024
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via
Benzinga
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
↗
December 02, 2024
Via
Benzinga
Glaukos Announces Participation in Upcoming Investor Conferences
November 08, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
↗
November 05, 2024
Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.
Via
Benzinga
Glaukos Announces Third Quarter 2024 Financial Results
November 04, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
October 16, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
October 14, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
October 09, 2024
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
